ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

J&J's Simponi Helps Colitis Patients In Clinical Trial

By Peter Loftus Of DOW JONES NEWSWIRES Johnson & Johnson (JNJ) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial. The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S. Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider. J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011. J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments. Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea. According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego. In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients. The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved. As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma. The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study. J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year. J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney. Abbott Laboratories (ABT) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication. Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
12/12/201402:30:11Abbott Laboratories Acquisition
11/18/201415:08:36Zoetis Unveils $500 Million Stock Buyback Plan -- Update
11/18/201408:07:30Zoetis Unveils $500 Million Buyback Plan
11/17/201409:02:52Zoetis to Buy Abbott's Animal Health Assets for $255 Million
10/22/201409:51:50U.S. Hot Stocks: Hot Stocks to Watch
10/19/201405:47:20MARKET SNAPSHOT: More Than 1/3 of Dow Stocks To Report This Week
09/26/201413:25:22Abbott Laboratories ABT Announces Acquisition of CFR Pharmaceuticals
07/14/201418:35:14MARKET SNAPSHOT: U.S. Stocks: Dow Closes Above 17,000
07/14/201418:30:00MARKET SNAPSHOT: U.S. Stocks Rise On Earnings, M&A News
07/14/201418:24:15MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,000, Eyes Record Close
07/14/201418:23:23MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,000 Again As Citi Rallies
07/14/201418:23:10MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,0000 Again As Citi...
07/14/201418:21:57Abbott Flees Struggling Business to Explore New Deals -- Market...
07/14/201418:20:11MARKET SNAPSHOT: U.S. Stocks: Futures Climb; Citigroup Results...
07/13/201406:18:25MARKET SNAPSHOT: Tech, Bank Earnings To Test Economic Recovery
06/23/201418:00:13Abbott to Acquire Russian Drug Maker Veropharm
06/16/201402:30:09Abbott Laboratories Statement re Stock Retirement Program Annual...
05/19/201402:30:13Abbott Laboratories Statement re Current Report of Form 8-K
05/15/201418:00:08Third Point Adds New Stakes in American Airlines, Anheuser-Busch
04/29/201402:30:47Abbott Laboratories Statement re Current Report on Form 8-K

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad